MTOR and Huntington disease: Among key endpoints reaching statistical significance in all comparison sets (i.e. PCa versus either Hyper or DF or HD), we found components and interactors of the MAP-kinase/mTOR pathway [58] such as TGF-β, phospho–β-Catenin_T41/S45 (β-Catenin_pT41/pS45) and phospho–c-Myc_T58/S62 itself (Fig. 4A and Tables S2–4, gray boxes), eventually underlying a common aberrant pathway route (Fig. S7B).